Stem Cell Motor Neuron Differentiation via Transcription Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into motor neurons are slow, asynchronous, and fail to reproduce the intrinsic properties of native motor neurons, particularly those from patients with neurodegenerative diseases, leading to low reproducibility and inefficiency in drug screening and therapeutic applications.
Innovation Solution
Introducing Ngn2, Lhx3, and Isl1 genes into pluripotent stem cells, followed by their induced expression, facilitates prompt and synchronized differentiation into motor neurons, with the ability to suppress cell death in ALS-derived cells and produce Aβ peptides characteristic of Alzheimer's disease, using a method that can be therapeutically applied or used for drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional differentiation methods (SFEB, SDIA, matrigel culture, cytokine methods) are used to generate neurons from pluripotent stem cells, then neurons can be obtained, but the process takes several months and produces asynchronous differentiation with low uniformity
Solution Approach 1:
The patent introduces and expresses neural lineage-specific transcription factors (Ascl1, Brn2, Myt1l) in pluripotent stem cells before the actual differentiation process. This preliminary introduction of differentiation cues enables the cells to rapidly and synchronously differentiate into neurons within 6-11 days, eliminating the need for prolonged conventional differentiation protocols that take several months.
Solution Approach 2:
The patent changes the temporal and molecular parameters of differentiation by using forced expression of specific transcription factors rather than gradual, slow differentiation. This parameter change transforms the differentiation process from a slow, asynchronous natural process to a rapid, synchronized artificial process, achieving both time reduction and improved uniformity.
2Reliability
If conventional differentiation methods are used, then neurons can be generated, but the neurons do not sufficiently possess intrinsic properties of neurons or reproduce disease phenomena
Solution Approach 1:
The patent introduces neural lineage-specific transcription factors (Ascl1, Brn2, Myt1l) that are critical for neuronal identity and function before differentiation occurs. This preliminary action ensures that the resulting neurons inherit the intrinsic properties and disease-specific characteristics of the original pluripotent stem cells, enabling reliable reproduction of neuronal functions and disease phenomena such as Aβ peptide production in Alzheimer's disease models.
3Productivity
If forced expression of transcription factors is used to accelerate differentiation, then neurons are obtained in short time (6-11 days), but differentiation synchrony and reproducibility of original properties are insufficient
Solution Approach 1:
The patent combines multiple neural lineage-specific transcription factors (Ascl1, Brn2, Myt1l) into a single forced expression system. This merging of multiple differentiation cues into one approach ensures that all necessary transcriptional programs are activated simultaneously, achieving both rapid neuron generation (6-11 days) and high differentiation synchrony with reliable reproduction of neuronal properties and disease phenotypes.
Data Source
Figure 1A~1H
Figure 2A~2C
Figure 3A~3D
AI summary
The present invention aims to provide a method of producing motor neurons/neurons that sufficiently reproduce intrinsic properties of motor neurons/neurons, especially of the motor neurons/neurons in patients, from pluripotent stem cells promptly and synchronically, and a pluripotent stem cell capable of differentiating into a neuron or a motor neuron promptly and synchronically after a drug treatment. A method of generating a motor neuron from a pluripotent stem cell, comprising the following steps in order from (1) to (2): (1) introducing one or more nucleic acids encoding Lhx3, Ngn2, and Isl1 into a pluripotent stem cell; and (2) maintaining expression of the Lhx3, Ngn2, and Isl1 for three days or more.